408 related articles for article (PubMed ID: 30066579)
1. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
2. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
3. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X
Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333
[TBL] [Abstract][Full Text] [Related]
4. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
5. Targeting Deubiquitinases in Cancer.
Bednash JS; Mallampalli RK
Methods Mol Biol; 2018; 1731():295-305. PubMed ID: 29318562
[TBL] [Abstract][Full Text] [Related]
6. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Mooneyham A; Bazzaro M
Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
[TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
Soave CL; Guerin T; Liu J; Dou QP
Cancer Metastasis Rev; 2017 Dec; 36(4):717-736. PubMed ID: 29047025
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitylating enzymes and drug discovery: emerging opportunities.
Harrigan JA; Jacq X; Martin NM; Jackson SP
Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
10. Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.
Chen X; Yang Q; Xiao L; Tang D; Dou QP; Liu J
Cancer Metastasis Rev; 2017 Dec; 36(4):655-668. PubMed ID: 29039082
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of Deubiquitinases (DUBs) in parasites: A foresight review.
Kumar P; Kumar P; Mandal D; Velayutham R
Front Cell Infect Microbiol; 2022; 12():985178. PubMed ID: 36237424
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Proteasomal Deubiquitinase by Silver Complex Induces Apoptosis in Non-Small Cell Lung Cancer Cells.
Chen X; Yang Q; Chen J; Zhang P; Huang Q; Zhang X; Yang L; Xu D; Zhao C; Wang X; Liu J
Cell Physiol Biochem; 2018; 49(2):780-797. PubMed ID: 30165348
[TBL] [Abstract][Full Text] [Related]
13. Proteasome-associated deubiquitinases and cancer.
Mofers A; Pellegrini P; Linder S; D'Arcy P
Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486
[TBL] [Abstract][Full Text] [Related]
14. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
15. Hinokitiol copper complex inhibits proteasomal deubiquitination and induces paraptosis-like cell death in human cancer cells.
Chen X; Zhang X; Chen J; Yang Q; Yang L; Xu D; Zhang P; Wang X; Liu J
Eur J Pharmacol; 2017 Nov; 815():147-155. PubMed ID: 28887042
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates.
Trulsson F; Akimov V; Robu M; van Overbeek N; Berrocal DAP; Shah RG; Cox J; Shah GM; Blagoev B; Vertegaal ACO
Nat Commun; 2022 May; 13(1):2736. PubMed ID: 35585066
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
18. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
Staszczak M
Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
[TBL] [Abstract][Full Text] [Related]
19. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy.
Aliabadi F; Sohrabi B; Mostafavi E; Pazoki-Toroudi H; Webster TJ
Open Biol; 2021 Apr; 11(4):200390. PubMed ID: 33906413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]